Abstracts

Week 144 Resistance Analyses of the Phase 3 EVG/COBI/FTC/TDF Studies

Background: Two phase 3, randomized, blinded, studies of elvitegravir/cobicistat/emtricitabine/tenofovir DF (EVG/COBI/FTC/TDF) in treatment-naïve subjects are ongoing (Studies 102 and 103). The week (W) 144 responses (Missing = Failure) were durable and similar for EVG/COBI/FTC/TDF vs. efavirenz ([EFV]/FTC/TDF) (82% vs 78%) and EVG/COBI/FTC/TDF vs. ritonavir-boosted atazanavir (ATV+RTV)+FTC/TDF (81% vs 79%). Resistance analyses through W144 are presented.…

Emergent and Detectable Proviral DNA Drug Resistance in a Community Treatment Program

Background: Drug resistance mutations (DRM) may circulate in HIV RNA and persist in CD4 cell DNA despite antiretroviral therapy (ART). To determine risks for transmission and community reservoirs of DRM, DNA genotype was assessed from PBMC DNA of viremic and suppressed ART recipients in a community clinic population. Methodology: HIV-1 sequences from consecutive consenting patients…

Rilpivirine-Associated Resistance in HIV-1 DNA in Suppressed Patients Pretreated by NNRTIs

Background: First generation NNRTI (efavirenz and nevirapine) failure is associated with a rapid selection of resistance-associated mutations (RAMs) which may impact on etravirine or rilpivirine susceptibility. Unfortunately in well suppressed patients historical resistance genotypes from plasma do not provide information regarding rilpivirine and etravirine-resistance. Our objective was to determine the presence of RAMs to rilpivirine,…

Acquired Drug-Resistance Mutations and Mortality Among HIV Patients on First-Line ART

Background: The potential long-term clinical risks of staying on failing nucleoside reverse-transcriptase inhibitor/non-nucleoside reverse-transcriptase inhibitor (NRTI/NNRTI)-based first-line antiretroviral treatment (ART) regimens and acquired drug-resistance mutations (DRMs) have not been well elucidated. Methodology: The study population included adult HIV patients who were initially ART-naive and who started first-line regimens between 2003-2005 at two sentinel sites in…

Etravirine/Rilpivirine-Specific Mutations Selected by EFV and NVP in Kenyan Patients Failing ART

Background: Antiretroviral drugs may produce different mutation patterns in different HIV-1 subtypes. We report here on the appearance of drug resistance mutations unique to etravirine and rilpilvirine exposure occurring in Kenyan patients with non-B subtypes failing first line therapy with neviripine or efavirenz. Methodology: RV288 is a multi-center PEPFAR Basic Program Evaluation that is being…

High HIV Resistance and Mutation Accrual at Low Viral Loads Upon 2nd-Line Failure in Western Kenya

Background: World Health Organization (WHO) defines antiretroviral treatment (ART) failure as HIV viral load (VL) >1000 copies/mL in resource limited settings (RLS). 2nd-line ART failure with drug resistance can limit subsequent regimens, more in settings with limited VL and resistance testing and delayed failure diagnosis. Resistance data upon 2nd-line failure in RLS are limited, particularly…

Drug Resistance After 2nd-Line Failure Can Be Managed Using WHO-Recommended Regimens in Nigeria

Background: In sub-Saharan Africa only a limited number of antiretroviral drugs is available. Virological failure, and subsequent drug resistance, during second-line treatment can therefore have substantial clinical ramifications as it can result in complete loss of therapeutic options. The Institute for Human Virology-Nigeria (IHVN), a US PEPFAR implementing partner, provides antiretroviral therapy (ART) to over…

Sociodemographic Determinants of HIV Drug Resistance in British Columbia Canada

Background: Baseline clinical factors and adherence to HAART are associated with resistance development after therapy. However, the interplay between sociodemographic and clinical factors influencing resistance development has not been well examined at a population level. Methodology: A cohort of HIV-positive persons accessing treatment from the BC-CfE Drug Treatment Program (DTP) from 1996-2012 was followed longitudinally.…